About Eternygen
Eternygen GmbH, based in Berlin, was founded in 2012 and researches and develops innovative drugs in collaboration with a network of internationally renowned researchers and research companies. Eternygen's core competence lies in the research and development of drugs for nutrition-related metabolic diseases, which have increased massively worldwide in recent decades. The focus is on the sodium-coupled citrate transporter NaCT, a key protein in fat metabolism, which is a promising target for the treatment of fatty liver, diabetes as well as obesity.
The aim is to develop a drug that addresses these widespread diseases effectively and particularly safely through targeted correction of the causative metabolic defect.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
- Industry : Pharma
Here you will find Eternygen GmbH
Last viewed contents
Valeo Pharma announces Richard J. MacKay as Chairman
Cornell Lab of Ornithology - Ithaca, USA
Arius announces new findings in Trop-2 and CD59 CANCER antibody programs - CD59 antibody uses novel approach to "de-cloak" cancers
FluIT Biosystems GmbH - Wendelsheim, Germany
Lipid Therapeutics GmbH: - Heidelberg, Germany
FRIEDRICHS FILTERSYSTEME GMBH - Wassenberg, Germany
Amgen Names Yuji Orihara President, Amgen KK
Amgen and Genentech settle patent dispute
Amgen Names Robert Bradway Executive Vice President and Chief Financial Officer
Prednisone
Pharma Stulln GmbH - Stulln, Germany
